Ulcerative Colitis

As part of its efforts for OAPI, Milwaukee-based BVK/G will develop and implement the strategic marketing plan, physician referral program, professional advisory boards, and public relations efforts.

"We are very excited and honored to partner with Otsuka America Pharmaceuticals on this project," notes Bob Gessert, president of BVK/G.

"GMA will be first-in-class for the treatment of irritable bowel disease.

This new therapy will provide patients with an alternative to other current medical treatments currently on the market.

The strategic market development and physician referral process will be two key components critical to the success for the Adacolumn at launch." GMA, currently approved and on market in Japan, is an apheresis process that selectively removes the granulocytes and monocytes from the blood.

These blood cells have long been known to cause the chronic inflammation and eventual destruction of the intestinal lining.

Clinical studies have demonstrated as much as a twelve-month remission utilizing GMA with the benefit of repeating the procedure if needed.

"We are pleased to be working with BVK/G," says Rob Kemp, Manager of Commercial Development.

"Their clinical insights and strategic thinking have proven to be extremely valuable and contin...

Read more...